Basic Information
| LncRNA/CircRNA Name | MEG3 |
| Synonyms | MEG3, FP504, GTL2, LINC00023, NCRNA00023, PRO0518, PRO2160, onco-lncRNA-83, prebp1 |
| Region | GRCh38_14:100779410-100861031 |
| Ensemble | ENSG00000214548 |
| Refseq | NR_002766 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | pancreatic neuroendocrine tumor |
| ICD-0-3 | C25 |
| Methods | qPCR etc. |
| Sample | cell lines (14M, M5, Men1) |
| Expression Pattern | up-regulated |
| Function Description | In the absence of Meg3, these c-Met regions displayed distinctive enhancer-signature histone modifications. Furthermore, Meg3 relied on functional EZH2, a component of the Polycomb Repressive Complex 2 (PRC2) to inhibit c-Met expression. Another mechanism of lncRNA-mediated regulation of gene expression utilized triplex forming GA-GT rich sequences. Transfection of such motifs from Meg3 RNA, termed triplex forming oligos (TFOs), in MIN6 cells, suppressed c-Met expression and enhanced cell proliferation, perhaps by modulating other targets. This study comprehensively establishes epigenetic mechanisms underlying Meg3 control of c-Met and the oncogenic consequences of Meg3 loss or c-Met gain. These findings have clinical relevance for targeting c-MET in PNETs. |
| Pubmed ID | 28847847 |
| Year | 2017 |
| Title | The Long Non-Coding RNA MEG3 is an Epigenetic Determinant of Oncogenic Signaling in Functional Pancreatic Neuroendocrine Tumor Cells |
External Links
| Links for MEG3 | GenBank HGNC NONCODE |
| Links for pancreatic neuroendocrine tumor | OMIM COSMIC |